Prove Which marketing dollars actually drive patient uptake.
Marketing mix modeling and incrementality testing for science - driven pharma and biopharma brands - turning marketing spend into a measurable, accountable system
I help science-driven pharma and biopharma leaders prove which marketing dollars are actually driving patient uptake — and which aren't. Using marketing mix modeling and incrementality testing, I replace guesswork with evidence: which channels, messages, and investments are truly moving adoption versus riding on baseline demand. This isn't open-ended strategy work — it's a disciplined, recurring analysis that turns your marketing spend into a measurable, accountable system, so every dollar has a clear line to patient impact and commercial results.
Interested in accelerated marketing impact?
Did You know?
Nearly two-thirds of pharma marketers can't connect their website activity to actual prescription fills, and many lose visibility entirely once patients move beyond brand-controlled channels — 83% of marketers struggle to connect website activity to prescription fills, according to a 2026 benchmark survey. Freshpaint/DigiPharma Insights Freshpaint
Third-party tracking is disappearing, and pharma measurement is shifting accordingly — instead of asking which exact ad drove a specific prescription, teams are now asking how each channel contributed to overall lift, using media mix modeling built on historical spend and performance data rather than user-level tracking. Pharma Marketing Network Pharma-mkting
Brands that adopt causally-validated marketing mix modeling see real efficiency gains — often improving media efficiency by 10-30%. Measured Measured
The gap between disciplined and undisciplined measurement is widening — organizations running always-on MMM, leveraging AI optimization, and dynamically reallocating budget based on real-time performance are pulling ahead, while those relying on annual, manual analysis are falling behind measurably, based on 170+ marketing mix studies across 80+ pharma brands. Axtria Axtria
Nearly 66% of drug launches miss pre-launch sales expectations, and 40-50% still fail to meet commercial targets even among mid- and large-cap companies. LinkedIn (kept from your existing site — still directly relevant to the case for measurement)
Targeted support and encouragement through years of experience
+20 YEARS
Experience
1000+
Projects
100%
Confident
one offer. one discipline. measurable results.
A fixed-scope, recurring retainer that answers one question every quarter: which marketing investments are actually working. No open-ended hours, no scope creep - just a clear, recurring readout on spend efficiency.